

知情同意书

研究背景 山东省肿瘤防治研究院的王琳琳医师将报告您的病例。这项研究经山东省肿瘤防治研究院伦理审查委员会审查通过。本知情同意书为您提供有关这项研究的研究目的、过程与方法，请您仔细阅读。如果您同意参加研究，请在表格下方签字。

研究目的 晚期胰腺癌应用阿帕替尼尚无相关报道。我们希望将此病例写文报道来为更多的临床医生提供相关经验。

研究过程与方法 我们会检索相关文献并总结他们。另外，您的医疗记录将被收集并报告。

研究意义 您的个案报告将帮助医生做出诊断和治疗。此外，它将为胰腺癌并抗血管生成药物的研究人员提供有价值的信息。

隐私政策 研究人员将保护您的隐私。

声明 参加研究是完全自愿的。如果您不想则不必参加。您也可以在任何时间退出研究。如果研究完成之前退出，您不会受到任何惩罚，也不会损失任何利益。

我已详细阅读知情同意书，我同意参加这项研究。

患者或监护人签名：付玉原

关系：夫妻

日期：2017.5.23

Informed Consent Form

Research background

Your case will be reported by Dr Lin-lin Wang of Shandong Cancer Hospital & Institute. This study was approved by the ethical review committee of Shandong Cancer Hospital & Institute. This form gives you important information about the study. It describes the purpose, process and method of the study, and please take time to review this information carefully. If you decide to take part in the study, you will be asked to sign this form.

Research purposes

There is no related reports about metastatic pancreatic cancer using apatinib. The case is reported to provide experiences for clinician.

Research process and methods

We will review the related literatures and summarize them. Otherwise your medical records will be collected and reported.

Research significance

Your case report will help doctors make a diagnosis, and perform treatment. Furthermore, it will provide some information for researchers on pancreatic cancer and anti-angiogenesis therapy.

Privacy policy

Researchers will protect your privacy.

Statement

Taking part in this study is completely voluntary. You do not have to participate if you don't want to. You may also leave the study at any time. If you leave the study before it is finished, there will be no penalty to you, and you will not lose any benefits to which you are otherwise entitled.

Signature

I understand the information printed on this form. My questions so far have been answered. I agree to take part in this study.

Signature: Yu bao Fu

Date: 5/13/2017